Pfizer Inc. (NYSE: PFE) announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, a...
" Quotient Sciences, in collaboration with Centillion, has installed the revolutionary Biofoundry-in-a-Box (BiaB™) at its Alnwick site, marking a n...
" Abzena, a leading CDMO/CRO, now offers GMP cell-based potency assays at its UK and US sites, enhancing its support for complex biologics and ADC programs...
AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the European Union (EU) for the treatment of adult patients with ...
Eli Lilly and Company (NYSE: LLY) announced detailed results from the SUMMIT Phase 3 trial showing tirzepatide significantly reduced the risk of worsening ...
GSK plc (LSE/NYSE: GSK) announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating Bl...
- The global cell and gene therapy (CGT) industry is poised for remarkable growth, driven by significant advances in life sciences and robust investments...
Acquisition of a majority stake in GI Alliance, the country's leading gastroenterology management services organization, to ac...
Oxford Medical Products is pleased to announce positive topline results from the first randomised controlled trial (RCT) of Sirona, its innova...
Innovative Trials is the second fastest-growing, woman-powered UK company in the clinical research sector and in the top 200 overall, according to ...
Eli Lilly and Company (NYSE: LLY) announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization fo...
Symbiosis acquires a 20,000 sq/ft building in Stirling, UK, to house new high-tech medicines manufacturing capacity, financed by £1...
Survey findings from over 8,700 people in 12 countries show that half of those polled have inadequate understanding of HPV, with ne...
RoukenBio, the Collaborative Research Organisation (CRO) formerly known as Antibody Analytics, has today announced completion of the phase 2 expans...
© 2024 Biopharma Boardroom. All Rights Reserved.
